Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 131,539 | 173,338 | 266,319 | 177,849 | 97,594 |
| TOTAL | $145,633 | $196,580 | $284,749 | $187,797 | $103,061 |
| Non-Current Assets | |||||
| PPE Net | 9,171 | 12,399 | 17,743 | 13,369 | 1,613 |
| Other Non-Current Assets | 6,652 | 11,379 | 14,614 | 17,752 | 531 |
| TOTAL | $15,823 | $23,778 | $32,357 | $31,121 | $2,144 |
| Total Assets | $161,456 | $220,358 | $317,106 | $218,918 | $105,205 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,629 | 5,187 | 3,722 | 6,314 | 902 |
| Accrued Expenses | 7,828 | 8,292 | 10,906 | 6,590 | 2,468 |
| TOTAL | $16,996 | $17,993 | $19,110 | $16,623 | $3,857 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,091 | 5,321 | 691 | 652 | 0 |
| TOTAL | $2,091 | $5,321 | $8,468 | $12,923 | $N/A |
| Total Liabilities | $19,087 | $23,314 | $27,578 | $29,546 | $3,857 |
| Shareholders' Equity | |||||
| Common Shares | 54 | 54 | 54 | 6 | 14 |
| Retained earnings | -259,952 | -190,287 | -119,111 | -58,012 | -24,813 |
| Other shareholders' equity | -12,943 | -21,567 | 6,764 | 12,322 | 8,110 |
| TOTAL | $142,369 | $197,044 | $289,528 | $189,372 | $101,348 |
| Total Liabilities And Equity | $161,456 | $220,358 | $317,106 | $218,918 | $105,205 |